Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models

Laboratory Investigation

Volumn 80, Issue 4, 2000, Pages 557-573

  Bryant, Jerry ^a   Pham, Lan ^a   Yoshimura, Linda ^a   Tamayo, Archito ^a   Ordonez, Nelson ^a   Ford, Richard J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CONTROLLED STUDY; FEMALE; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; XENOTRANSPLANTATION;

EID: 0034088792     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780061     Document Type: Article

References (48)

1. Anonymous (1982). Non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135.
2. Beran M, Pisa P, Kantarjian H, Porwit A, and Bjorkholm (1994). Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol Pathol 8:135-154.
3. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, and Kantarjian H (1993). Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 53:3603-3610.
4. Bosma GC, Custer RP, and Bosma MJ (1983). A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530.
5. Bosma MJ and Carrol AM (1991). The SCID mouse mutant: Definition, characterization, and potential uses. Annu Rev Immunol 9:323-350.
6. Butcher EC, Williams M, Youngman K, Rott L, and Briskin M (1999). Lymphocyte trafficking and regional immunity. Adv Immunol 72:209-253.
7. Cesano A, Hoxie JA, Langem B, Nowell PC, Bishop J, and Santoli D (1992). The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 7:827-836.
8. Chelstrom LM, Gunther R, Simon J, Raimondi SC, Krance R, Crist WM, and Uckun FM (1994). Childhood acute myeloid leukemia in mice pretreated with radiation and anti-asialo GM1. Anticancer Res 84:20-26.
9. Custer RP, Bosma GC, and Bosma MJ (1985). Severe combined immunodeficiency (SCID) in the mouse: Pathology, reconstitution, neoplasms. Am J Pathol 120:464-477.
10. Deane M and Norton JD (1990). Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B-lineage leukemias. Eur J Immunol 20:2209-2217.
11. DeMartini RM, Turner RR, Boone DC, Lukes RJ, and Parker JW (1988). Lymphocyte immunophenotyping of B-cell lymphomas: A flow cytometric analysis of neoplastic and non-neoplastic cells in 271 cases. Clin Immunol Immunopath 49:365-379.
12. Dorshkind K, Pollack SB, Bosma MJ, and Phillips RA (1985). Natural killer cells are present in mice with severe combined immunodeficiency. J Immunol 134:3798-3801.
13. Drillenburg P, van der Voort R, Koopman G, Dragosics B, van Krieken JH, Kluin P, Meenan J, Lazarovits Al, Radaszkiewicz T, and Pals ST (1997). Preferential expression of the mucosal homing receptor integrin α4/37 in gastrointestinal non-Hodgkin's lymphomas. Am J Pathol 150:919-927.
14. Duchosal MA, Eming SA, McConahey PJ, and Dixon FJ (1992). The hu-PBL-SCID mouse model: Long-term human serologic evolution associated with the xenogeneic transfer of human peripheral blood leukocytes into SCID mice. Cell Immunol 139:468-477.
15. Felsher DW, Rhim SH, and Braun JA (1990). A murine model for B-cell lymphomagenesis in immunocompromised hosts - Natural killer cells are an important component of host resistance to premalignant B-cell lines. Cancer Res 50:7050-7056.
16. Fidler IJ (1986). Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 5:29-49.
17. Flavell DJ (1996). Modeling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: Practical applications. Hematol Oncol 14:67-82.
18. Ford R, Tamayo A, Martin B, Niu K, Claypool K, Cabanillas F, and Ambrus J (1995). Identification of B-Cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas. Blood 86:283-293.
19. Ford RJ, Bryant J, Claypool K, and Cabanillas F (1996). Human lymphoma models in SCID mice: Non-Hodgkin and Hodgkin's. Blood 88(Suppl 1):386a.
20. Ford RJ, Luthra R, Bryant J, Tamayo A, and Curiel T (1998). In vitro and in vivo models for mantle cell lymphoma. Blood 92:1288a.
21. Harris NL, Jaffe ES, Stein H, Bank PM, Chan JKL, Cleary ML, Delsol G, Christin De WP, Falini B, Gatter KC, Grogan TM, lsaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri MA, Ralfkiaer E, and Warnke SA (1994). A revised European-American Classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361-1392.
22. Herberman RB, Djeu JY, Kay D, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, and Puccetti P (1979). Natural killer cells: Characteristics and regulation of activity, Immunol Rev 44:44-70.
23. Herberman RB, Nunn ME, and Lavrin DH (1975). Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity, Int J Cancer 16:216-229.
24. Hesse JE, Lieber MR, and Gellert M (1987). Extrachromosomal DNA substrates in pre-B cells undergo inversion or deletion at immunoglobulin V-(D)-J joining signals. Cell 49: 1-9.
25. Isaacson PG (1999a). Gastric MALT lymphoma: From concept to cure. Ann Oncol 10:637-645.
26. Isaacson PG (1999b). Gastrointestinal lymphomas of T- and B-cell types. Mod Pathol 12:151-158.
27. Kamel-Reid S, and Dick JE (1988). Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 242:1706-1709.
28. Kiessling R, Klein E, and Wigzell H (1975). Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112-117.
29. Kiessling R and Wigzell H (1979). An analysis of the murine NK cell as to structure, function and biological relevance, Immunol Rev 44:166-208.
30. Kroon JFED, Kluin PM, Nelemans HC, Willemze R, and Falkenburg JHF (1994). Homing and antigenic characterization of a human Non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice. Leukemia 8:1385-1391.
31. Lauzon RJ, Siminovitch KA, Fulop GM, Phillips RA, and Roder JC (1986). An expanded population of natural killer cells in mice severe combined immunodeficiency (SCID) lack rearrangement and expression of T cell receptor genes. J Exp Med 164:1797-1801.
32. Lehmann MT, Saxon A, and Lehmann PV (1995). The human immune system in hu-PBL-SCID mice, Immunol Today 16: 529-533.
33. Lieber MR, Hesse JE, and Lewis S (1988). The defect in murine severe combined immune deficiency. Joining of signal sequences but not coding segments in V(D) J recombination. Cell 55:7-16.
34. Malynn B, Blackwell TK, and Fulop G (1988). The SCID affects the final step of the immunoglobulin VDJ recombinase mechanism. Cell 54:453-460.
35. Martino G, Anastasi J, Feng J, Mcshan C, DeGroot L, Quintans J, and Grimaldi LME (1993). The fate of human peripheral blood lymphocytes after transplantation into SCID mice. Eur J Immunol 23:1023-1028.
36. Menin C, Ometto L, Verones A, Roncella S, Corneo B, Montagna M, Coppola V, Veronese ML, Indraccolo S, Amadori A, De Rossi A, Ferrarini M, Chieco-Bianchi L, and D'Andrea E (1996). Analysis of Epstein-Barr Virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumors. Mol and Cellul Probes 10:453-461.
37. Mosier DE, Gulizia RJ, Baird SM, and Wilson DB (1988). Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335:256-259.
38. Mosier DE, Picchio GR, Baird SM, Kobayashi R, and Kipps TJ (1992). Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res 52:5552s-5553s.
39. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, and Arnold A (1991). A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 50:512-515.
40. Moynihan MJ, Bast MA, Chan WC, Delabie J, Wickert RS, Wu G, and Weisenburger DD (1996). Lymphomatous polyposis: A neoplasm of either follicular mantle or germinal center cell origin. Am J Surg Pathol 20:442-452.
41. Namikawa R, Ueda R, and Kyoizumi S (1993). Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 82:2526-2536.
42. Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, and Butcher EC (1988). Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 30:496-504.
43. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, and Arnold A (1991). Prad1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638-9642.
44. Sandhu J, Shpitz B, Gallinger S, and Hozumi N (1994). Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J lmmunol 152: 3806-3813.
45. Sawyers CL, Gishizky ML, Quan S, Golde DW, and Witte ON (1992). Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 79:2089-2098.
46. Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, and Ford RJ Jr (1997). Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 8:1071-1082.
47. Waller EK, Kamel OW, Cleary ML, Maumdar AS, Schick MR, Lieberman M, and Weissman IL (1991). Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: Requirement for a human lymphoid microenvironment. Blood 78: 2650-2665.
48. Zukerberg LR, Yang W-I, Arnold A, and Harris NL (1995). Cyclin D1 expression in non-Hodgkin's lymphomas. Am J Clin Pathol 103:756-760.